Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $87000.0.

  • UroGen Pharma's Capital Expenditures fell 937.5% to $87000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $387000.0, marking a year-over-year increase of 6398.31%. This contributed to the annual value of $295000.0 for FY2024, which is 5206.19% up from last year.
  • Per UroGen Pharma's latest filing, its Capital Expenditures stood at $87000.0 for Q3 2025, which was down 937.5% from $141000.0 recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Capital Expenditures peaked at $287000.0 during Q1 2021, and registered a low of $13000.0 during Q4 2022.
  • For the 5-year period, UroGen Pharma's Capital Expenditures averaged around $98166.7, with its median value being $85500.0 (2024).
  • As far as peak fluctuations go, UroGen Pharma's Capital Expenditures tumbled by 9356.44% in 2022, and later skyrocketed by 46000.0% in 2024.
  • Quarter analysis of 5 years shows UroGen Pharma's Capital Expenditures stood at $202000.0 in 2021, then plummeted by 93.56% to $13000.0 in 2022, then surged by 330.77% to $56000.0 in 2023, then surged by 105.36% to $115000.0 in 2024, then dropped by 24.35% to $87000.0 in 2025.
  • Its last three reported values are $87000.0 in Q3 2025, $141000.0 for Q2 2025, and $44000.0 during Q1 2025.